Nemorubicin

CAS : 108852-90-0

Ref. 3D-BN180615

Informations sur le produit

• Nom: Nemorubicin
• Synonymes: PNU 152243, (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[(2S)-2-methoxymorpholin-4-yl]-alpha-L-lyxo-hexopyranoside, (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-[(S)-2-methoxymorpholino]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranoside, (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (8S,10S)-, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-2,3,6-trideoxy-3-(2S)-2-methoxy-4-morpholinyl-.alpha.-L-lyxo-hexopyranosyloxy-, (8S,10S)-, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, [8S-[8α,10α(R*)]]-, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (8S,10S)-, DMM Dox, Fce 23762, Methoxy-Morpholynil-Doxorubicin, Methoxymorpholinyldoxorubicin, Mmrdx, Pnu 152243, (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-, 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-, [8S-[8α,10α(R*)]]-

Description

Nemorubicin is a drug that has been used in cancer gene therapy. It is stable and can form stable complexes with DNA. Nemorubicin binds to the human cytochrome P450 3A4 (CYP3A4) enzyme and blocks its activity, which may lead to an increase in the concentration of other drugs that are metabolized by CYP3A4, such as tacrolimus and cyclosporine A. Nemorubicin has been shown to be effective against solid tumours with low potency. Nemorubicin is a cytotoxic agent that inhibits protein synthesis by binding to the thymidine kinase (TK) enzyme, preventing it from converting thymidine into deoxyuridine monophosphate (dUMP). This inhibition leads to cell death by preventing DNA synthesis and repair mechanism.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 643.64 g/mol
• Formule: C₃₂H₃₇NO₁₃
• Degré de pureté: Min. 98 Area-%
• Couleur/Forme: Powder